bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, …
In a research report published Tuesday, J.P.
bluebird bio Inc (NASDAQ:BLUE) , a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based …
In a research report published May 6, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on bluebird bio Inc (NASDAQ:BLUE) with a price …
Quick SPDR S&P 500 ETF Trust (NYSE ARCA:SPY) forecast update: Back on November 10th 2014 we predicted a spring 2015 high of 2181 …
On April 29, Joshua Schimmer of Piper Jaffray released a report highlighting several biopharmaceutical companies tackling Sickle Cell Disease, or SCD. The hereditary blood disorder …
Following the annual J.P.
One of the more anticipated events of early 2015 played out on Friday – detailed results from an early study of Biogen Idec Inc's (NASDAQ:BIIB) experimental …
The latest in the onslaught of biotech initial public offerings, Spark Therapeutics (ONCE) priced at $23 on Thursday evening. Twelve hours later, the stock opened at …
2014 was an eventful year on Wall Street with many ups and downs. Although many analyst recommendations made in 2014 were profitable, many …
